// App-Quantinova.ai

EP987 : A PROSPECTIVE, NON-INTERVENTIONAL, MULTINATIONAL STUDY OF REAL-LIFE STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH ≥3 PRIOR LINES OF THERAPY: INTERIM DATA FROM LOCOMMOTION

Researchers

Presenter

  • Maria-Victoria Mateos

Principal Investigators

  • Valerio De Stefano

  • Aurore Perrot

  • Niels van de Donk

  • Hartmut Goldschmidt

  • Martin Kaiser

  • Ravi Vij

  • Francesca Gay

  • Annemiek Broijl

  • Anna Potamianou

  • Caline Sakabedoyan

  • Vadim Strulev

  • Jordan Schecter

  • Martin Vogel

  • Tonia Nesheiwat

  • Robert Wapenaar

  • Michel Delforge

  • Hermann Einsele

  • Philippe Moreau

Medical Centers

  • University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT),Heidelberg,Germania

  • Medical Affairs,Legend Biotech USA Inc,Piscataway,United States

  • Clinical Hematology,University Hospital Hotel-Dieu,Nantes,Frankrijk

  • Hospital Clinico Univ de Salamanca, Salamanca, Spain

  • EMEA Medical Affairs, Janssen Pharmaceutica, Beerse, Belgium

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • Division of Hematology, University of Turin, Turin, Italy

  • Department of Hematology, Erasmus MC Cancer Insitute, Rotterdam, Netherlands

  • D,Raritan,United States

  • Amsterdam UMC, Vrije Universiteit Amsterdam,Amsterdam,Niederlande

  • Janssen R&amp

  • EMEA Medical Affairs, Janssen-Cilag, Beirut, Lebanon

  • Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, United States

  • Section of Hematology, Department of Radiological and Hematological Sciences,Catholic University, Fondazione Policlinico A. Gemelli, IRCCS,Roma,Italy

  • Janssen-Cilag GmbH, Neuss, Germany

  • Janssen-Cilag BV, Breda, Netherlands

  • Institute for Cancer Research, London, United Kingdom

  • Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II,Würzburg,Deutschland

  • Janssen Global Services, Raritan, NJ, United States

  • Institut Universitaire du Cancer de Toulouse, Toulouse, France

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

Locations

  • Germany

  • United States

  • France

  • Spain

  • Belgium

  • Italy

  • Netherlands

  • Lebanon

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Non Interventional

  • Multinational

  • Prospective

Phase

  • NA

Study Id's

  • NCT04035226

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved